17β-HSD2 Inhibitors belong to a class of chemical compounds designed to target and inhibit the enzyme 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2). This enzyme plays a significant role in the metabolism of steroid hormones, particularly in the conversion of estradiol to estrone, a process crucial in maintaining hormone balance. Inhibitors of 17β-HSD2 are developed to interact with this enzyme, potentially disrupting its catalytic activity and affecting the interconversion of steroid hormones.
The development of 17β-HSD2 inhibitors is a complex and interdisciplinary process involving medicinal chemistry, structural biology, and biochemistry. Researchers seek to understand the three-dimensional structure of 17β-HSD2, as it provides insights into the enzyme's active sites and catalytic mechanisms. Techniques such as X-ray crystallography and cryo-electron microscopy are employed to visualize the enzyme's structure at the atomic level. Armed with this structural knowledge, medicinal chemists design and synthesize a variety of chemical compounds that can interact with 17β-HSD2, either by binding to its active sites or altering its conformation. These inhibitors undergo extensive testing and optimization to identify molecules with the highest binding affinity and inhibitory potency. Computational modeling plays a crucial role in predicting how different chemical structures might interact with 17β-HSD2 and guides the design of potential inhibitors. Additionally, researchers consider the physicochemical properties of 17β-HSD2 inhibitors to ensure their suitability for laboratory research and potential applications in understanding hormone metabolism and related processes. The development of 17β-HSD2 inhibitors contributes to our understanding of steroid hormone metabolism and its regulation, offering valuable tools for research in this field.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole may inhibit cytochrome P450 enzymes, potentially reducing steroidogenesis and indirectly affecting 17β-HSD2 expression by altering intracellular steroid levels. | ||||||
Trilostane | 13647-35-3 | sc-208469 sc-208469A | 10 mg 100 mg | $228.00 $1217.00 | 2 | |
Trilostane inhibits 3β-hydroxysteroid dehydrogenase, which may lead to altered steroid hormone levels and subsequently inhibit 17β-HSD2 expression. | ||||||
Aminoglutethimide | 125-84-8 | sc-207280 sc-207280A sc-207280B sc-207280C | 1 g 5 g 25 g 100 g | $42.00 $146.00 $541.00 $2060.00 | 2 | |
Aminoglutethimide inhibits the synthesis of steroid hormones, potentially decreasing the substrate availability and, thereby, expression of 17β-HSD2. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $134.00 $411.00 | ||
Exemestane is an aromatase inhibitor that may lower estrogen levels, potentially downregulating 17β-HSD2 expression in estrogen-responsive tissues. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $87.00 $147.00 | 5 | |
Letrozole selectively inhibits aromatase, leading to decreased estrogen synthesis. This decrease may influence the regulation of 17β-HSD2 expression. | ||||||
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $105.00 | 3 | |
Finasteride inhibits 5α-reductase, affecting dihydrotestosterone (DHT) levels, which may indirectly influence 17β-HSD2 expression due to altered androgen signaling. | ||||||
Dutasteride | 164656-23-9 | sc-207600 | 10 mg | $167.00 | 2 | |
Dutasteride, a dual 5α-reductase inhibitor, reduces DHT levels and may indirectly modulate 17β-HSD2 expression through changes in androgen receptor signaling. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Anastrozole is an aromatase inhibitor that reduces estrogen biosynthesis, which might influence 17β-HSD2 expression by modifying hormonal feedback mechanisms. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Mifepristone antagonizes glucocorticoid receptors and may affect steroid hormone receptor-mediated regulation, potentially influencing 17β-HSD2 expression. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone acts as a mineralocorticoid and androgen receptor antagonist, which might lead to changes in hormone-mediated signaling pathways that regulate 17β-HSD2 expression. | ||||||